Preparations

BP 2008: Compound Rhubarb Tincture.

Proprietary Preparations (details are given in Part 3) Cz.: Bukosan†; Ger.: Phytoestrol N; Pol.: Laxitab; Radirex; Rzewex.

C2: Bukosan†; Ger.: Prytoestrol N; Pol.: Laxitab; Radirex, Rzevex. Multi-ingredient: Arg: Calculina†; LX-30, Oralsone Topic; Parodium; Pyrałvex Austrol.: Betane Digestive Aid; Neo-Cleanse: Pyralvex; Aus-tria: Abfuhrtee†; Eucarbon; Eucarbon Herbal; Novocholin; Pyralvex; Saba-tif; Silberne; Belg:: Pyralvex; Brazz, Bilfef†; Bisuisan†; Boldopeptan†; Cam-omila; Eparema; Regulador Xavier N-2‡, Canod.: Extra Strong Formula 12†; Herbal Laxative; Herbalax; Herbolax; Cz.: Abdomilon†; Cynarosan†; Dr Theiss Rheuma Creme†; Dr Theiss Schweden Krauter; Dr Theiss Schwedenbitter; Pyralvex; Greies Cholagogae Planta; Zlucnikova Cajova mes; Fr:: Carres Paragsvilium; Depuratum, Parodium; Pyralvex; Resource Rhubagi; Ger.: Pyralvex; Gre: Pyralvex; Horg Kong; Hepatofalk; Pyralvex; Hung:: Bolus Laxans, Indon:: Pyralvex; Hn: Pyralvex; Israel: Davilla Encyp; Hung:: Bolus Laxans, Indon:: Pyralvex; Holif; Conlogic; Caranele alle Erbe Digestive; Colax; Critichol; Digelax†; Dis-Cinil Complex; Eparema; Epare-Amaro Medicinale†; Struolft; Melajax; Neoform†; Puntualax†; Pyralvex; Schia-mara Levul; Eucarbon; Kubal; Krenichs Maldifass†; Lactolas; Lassativi Vetegali; Magisbile†; Mepalax; Neoform†; Puntualax†; Pyralvex; Schia-mara Keudi; Lourathor; Ruba; Xenoform†; Puntualax†; Pyralvex; Schia-Hantol; Laxantol; Rhelax; Port.: Pyralvex; Rus:: Parodium (Tapoznym); SAM;: Heinoniskyrie; Lewensessen; Moulton; Herbal Extract; Praivex; Pariley: Boie Carminative (Carminasen); Pyralvex; Rus:: Parodium (Tapoznym); SAM;: Hennolskyrie; Lewensessen; Moulton; Herbal Extract; Praivex; Pariley: Boie Carminative (Carminasen; Pyralvex; Rus:: Parodium (Tapoznym); SAM;: Hennolskyrie; Lewensessen; Moulton; Herbal Extract; Praivex; Pariley: Boie Carminative (Carminasen; Pyralvex; Rus:: Parodium (Tapoznym); SAM;: Hennolskyrie; Lewensessen; Moulton; Herbal Extract; Praivex; Pariley: Boie Carminative (Carminasen; Pyralvex; Rus:: Parodium (Tapoznym); SAM;: Herboniskyrie; Lewensessen; Moulton; Herbal Extract; Praivex; Pariley: Boie Carminative Ionici Laxantol, Knelax, Port.: Pyralvex, Wus.: rarodium (TaboAuyM), S.Afr.: Helmontskruie; Lewenessens; Moultons Herbal Extract, Pyralvex, Rubilax†; Wonderkroonessens, Singopore: Pyralvex, Spain: Cristaxo; Lax-ante Bescansa Aloico; Menabil Complex†; Pyralvex, Solucion Schoum; Switz.: Padma-Lax; Padmed Laxar, Pyralvex, Schweden-Mixtur H nouvelle formulation; Thai.: Pyralvex, Turk.: Eucarbon; Karboseptin; Piraldyne; Pyralvex, UK: Acidosis; Digestive; Fam-Lax; Fam-Lax Senna: HRI Golden Seal Digestive; Indian Brandee; Jacksons Herbal Laxative; Pegina; Pyralvex, UK Rhuaka; Stomach Mixture; Wind & Dyspepsia Relief; **USA:** Black-Draught†; **Venez.:** Cynascool; Natrossil; Orafilm†; Pinvex; Pyralvex†; Rheu-Tarx I.

Roxatidine Acetate Hydrochloride


(BANM, USAN, rINNM)

Hidrocloruro de acetato de roxatidina; Hoe-760; Hoe-062 (roxatidine); Pifatidine Hydrochloride; Roxatidine, Acétate Chlorhydrique de; Roxatidini Acetati Hydrochloridum; TZU-0460. N-{3-[(α-Piperidino-m-tolyl)oxy]propyl}glycolamide acetate monohydrochloride.

Роксатидина Ацетат Гидрохлорид

C₁₇H₂₆N₂O₃,C₂H₂O,HCl = 384.9. CAS — 78273-80-0 (roxatidine); 97900-88-4 (roxatidine hydrochloride); 78628-28-1 (roxatidine acetate); 93793-83-0 (roxatidine acetate hydrochloride). ATC. -– A02BA06.

ATC Vet — QA02BA06.





Pharmacopoeias. In Jpn.

Stability. The stability of roxatidine acetate hydrochloride in parenteral nutrition solutions was influenced by storage temperature and amino acid content and composition.1

Oh J, et al. Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations. Am J Health-Syst Pharm 2005; 62: 289–91.

Adverse Effects and Precautions

As for Cimetidine, p.1716.

Interactions

Unlike cimetidine (p.1718) roxatidine does not appear to affect cytochrome P450, and therefore is considered to have little effect on the metabolism of other drugs. However, like other H2-antagonists its effects on gastric pH may alter the absorption of some other drugs.

Pharmacokinetics

Roxatidine acetate hydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract with peak concentrations in plasma occurring about 1 to 3 hours after doses by mouth. It is rapidly hydrolysed to the active desacetyl metabolite, roxatidine, by esterases in the liver, small intestine, and serum. Over 90% of a dose is excreted in the urine as roxatidine and other metabolites. The elimination half-life of roxatidine is about 6 hours and is prolonged in renal impairment. Small amounts of roxatidine have been reported to be distributed

into breast milk.

Uses and Administration

Roxatidine acetate hydrochloride is an H2-antagonist with actions and uses similar to those of cimetidine (p.1719).

In the management of peptic ulcer disease the oral dose is 150 mg at bedtime or 75 mg twice daily for 4 to 6 weeks. Where appropriate a maintenance dose of 75 mg at bedtime may be given to prevent the recurrence of ulcers. In gastro-oesophageal reflux disease the recommended dose is 150 mg at bedtime or 75 mg twice daily for 6 to 8 weeks. Gastritis has been managed with 75 mg once daily in the evening, and a dose of 75 mg twice daily has been used for Zollinger-Ellison syndrome.

When used as a pre-anaesthetic medication, an oral dose of roxatidine acetate hydrochloride 75 mg is given in the evening on the day before surgery and repeated 2 hours before the induction of anaesthesia; alternatively a single dose of 150 mg may be given the night before surgery.

Roxatidine acetate hydrochloride may also be given intravenously for the treatment of upper gastrointestinal tract haemorrhage in a dose of 75 mg twice daily by slow intravenous injection or by intravenous infusion.

For dosage in renal impairment, see below.

O Reviews

1. Murdoch D. Roxatidine acetate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. *Drugs* 1991; **42**: 240–60.

Administration in renal impairment. The dosage of roxatidine acetate hydrochloride should be reduced in patients with renal impairment. Suggested oral doses, based on creatinine clearance (CC), for patients on acute therapy are:

· CC 20 to 50 mL/minute: 75 mg at bedtime

· CC less than 20 mL/minute: 75 mg every 2 days

However, results in 6 patients with chronic renal failure and CC less than 20 mL/minute indicated that giving the recommended dose of roxatidine acetate hydrochloride, 75 mg every other day, was inadequate to maintain gastric pH above 4 for more than 6 hours. Subsequent study in 8 patients showed that a dose of 75 mg daily was well tolerated and effective.1

Gladziwa U, et al. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency. Br J Clin Pharma-col 1995; 39: 161–7.

Preparations

Proprietary Preparations (details are given in Part 3) Gen: Roxit†; Gr.: Roxane†; India: Rotane; Ital.: Gastralgin; Neo H2; Roxit; Jpn: Altat; Neth.: Roxit†; S.Afr.: Roxit†; Spain: Roxiwas†; Zarocs.

Senna

Alexandriai szenna termés (senna pods, Alexandrian); Listek senesu (senna leaf); Plod kasie ostrolisté (senna pods, Alexandrian); Plod kasie úzkolisté (senna pods, Tinnevelly); Sen; Séné de Khartoum ou d'Alexandrie, fruit de (senna pods, Alexandrian); Séné de l'Inde ou de Tinnevelly, fruit de (senna pods, Tinnevelly); Séné, feuille de (senna leaf); Sennabalja, alexandrinsk (senna pods, Alexandrian); Sennabalja, Tinnevelley- (senna pods, Tinnevelley); Sennae folium (senna leaf); Sennae fructus acutifoliae (senna pods, Alexandrian); Sennae fructus angustifoliae (senna pods, Tinnevelly); Sennanpalko, Aleksandrian (senna pods, Alexandrian); Sennanpalko, Tinnevelleyn (senna pods, Tinnevelley); Sennový list (senna leaf); Senų lapai (senna leaf); Senų vaisiai (senna pods, Alexandrian); Siauralapių senų vaisiai (senna pods, Tinnevelly); Sinameki; Śzennalevél (senna leaf); Tinevelly szenna termés (senna pods, Tinnevelly).

Кассия Остролистная (Alexandrian senna); Сенна Остролистная (Alexandrian senna); Александрийский Лист (Alexandrian senna leaf)

CAS — 8013-11-4. ATC — A06AB06.

ATC Vet - QA06AB06.

Description. Senna obtained commercially from Cassia senna (C. acutifolia) (Leguminosae) is known as Alexandrian senna or Khartoum senna and that from Cassia angustifolia (Leguminosae) as Tinnevelly senna.

Pharmacopoeias. Senna fruit, from Alexandrian and Tinnevelly senna is included in Eur. (see p.vii), Int., and US. Senna leaf, from Alexandrian or Tinnevelly senna or both, is included in Chin., Eur., Int., Jpn, and US.

Ph. Eur. 6.2 (Senna Pods, Alexandrian; Sennae Fructus Acutifoliae; Alexandrian Senna Fruit BP 2008). The dried fruit of Cassia senna (Cassia acutifolia) containing not less than 3.4% of hydroxyanthracene glycosides, calculated as sennoside B $(C_{42}H_{38}O_{20} = 862.7)$ with reference to the dried drug. Protect from light and moisture.

Ph. Eur. 6.2 (Senna Pods, Tinnevelly; Sennae Fructus Angustifoliae; Tinnevelly Senna Fruit BP 2008). The dried fruit of Cassia angustifolia containing not less than 2.2% of hydroxyanthracene glycosides, calculated as sennoside B ($C_{42}H_{38}O_{20} = 862.7$) with reference to the dried drug. Protect from light and moisture.

Ph. Eur. 6.2 (Senna Leaf; Sennae Folium). The dried leaflets of Cassia senna (=Cassia acutifolia), known as Alexandrian or Khartoum senna, or Cassia angustifolia, known as Tinnevelly senna, or a mixture of the two species. It contains not less than 2.5% of hydroxyanthracene glycosides, calculated as sennoside B ($C_{42}H_{38}O_{20} = 862.7$) with reference to the dried drug. Protect from light and moisture.

USP 31 (Senna Leaf). The dried leaflet of Cassia acutifolia, known in commerce as Alexandria senna, or Cassia angustifolia, known in commerce as Tinnevelly senna (Leguminosae). Protect from moisture and from light.


USP 31 (Senna Pods). The dried ripe fruit of Cassia acutifolia (Alexandrian senna) or Cassia angustifolia (Tinnevelly senna) containing not less than 3.4% or 2.2% respectively of anthraquinone glucosides, calculated as sennosides, on the dried basis. Protect from moisture and from light.

Sennosides

Senósidos

Сеннозиды

CAS — 81-27-6 (sennoside A); 128-57-4 (sennoside B); 52730-36-6 (sennoside A, calcium salt); 52730-37-7 (sennoside B, calcium salt).



(sennoside A)

Pharmacopoeias. In US.

USP 31 (Sennosides). A partially purified natural complex of anthraquinone glucosides found in senna, isolated from Cassia acutifolia or Cassia angustifolia as calcium salts. It is a brownish powder. Soluble 1 in 35 of water, 1 in 2100 of alcohol. 1 in 3700 of chloroform, and 1 in 6100 of ether. A 10% solution in water has a pH of 6.3 to 7.3. Store at a temperature of 20° to 25°. Protect from moisture and from light.

Adverse Effects

Senna may cause mild abdominal discomfort such as colic or cramps. Prolonged use or overdosage can result in diarrhoea with excessive loss of water and electrolytes, particularly potassium; there is also the possibility of developing an atonic non-functioning colon. Anthraquinone derivatives may colour the urine yellowish-brown at acid pH, and red at alkaline pH. Reversible melanosis coli has been reported following chronic use.

Abuse. Prolonged use or abuse of senna laxatives has been associated with finger clubbing,¹⁻⁵ hypokalaemia³ and tetany,¹ hypertrophic osteoarthropathy,⁴⁻⁵ intermittent urinary excretion of aspartylglucosamine,² hypogammaglobulinaemia,³ reversible cachexia,3 and hepatitis6 or hepatic failure.7 In one case, nephrocalcinosis was attributed to hypercalcaemia caused by excessive ingestion of calcium sennosides.5

- 1. Prior J, White I. Tetany and clubbing in patient who ingested large quantities of senna. *Lancet* 1978; **ii:** 947.
- 2. Malmquist J, et al. Finger clubbing and aspartylglucosamine e cretion in a laxative-abusing patient. Postgrad Med J 1980; 56: 862-4
- 3. Levine D, et al. Purgative abuse associated with reversible cachexia, hypogammaglobulinaemia, and finger clubbing. Lancet 1981; i: 919-20.
- Armstrong RD, et al. Hypertrophic osteoarthropathy and purgative abuse. BMJ 1981; 282: 1836.
 Lim AKH, et al. Anorexia nervosa and senna misuse: nephrocal-
- cinosis, digital clubbing and hypertrophic osteoarthropathy. *Med J Aust* 2008; **188**: 121–2.
- 6. Beuers U, et al. Hepatitis after chronic abuse of senna. Lancet 1991; **337:** 372–3.
- 7. Vanderperren B. et al. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother 2005; 39: 1353-7.

Effects on the liver. Hepatitis has been reported in a patient drinking herbal tea containing senna. The patient was found to be a poor metaboliser for hepatic detoxification reactions; the authors cautioned against even small doses of herbal preparations in such patients.

Hepatitis and hepatic failure have also been reported after abuse of senna laxatives, see Abuse, above

Seybold U, et al. Senna-induced hepatitis in a poor metabolizer. Ann Intern Med 2004; 141: 651.

Hypersensitivity. Hypersensitivity reactions manifesting as asthma and rhinoconjunctivitis have been reported in those manufacturing¹ or dispensing² senna products. However, a study of 125 workers involved in the manufacture of laxatives found only 4 cases of occupational asthma, although sensitisation to senna or ispaghula dust was present in 18 and 9 of the workers

The symbol † denotes a preparation no longer actively marketed

respectively, and other airway, eye, and skin symptoms were relatively frequent.3

A 2-year history of pruritic scaly erythematous plaques on the palmoplantar surfaces was reported⁴ by a patient who had taken a sennoside laxative for 20 years. The lesions subsided over about 6 weeks on stopping the drug, and reappeared over the course of 8 weeks on restarting sennoside. However, patch testing and lymphocyte stimulation tests for sennoside were negative.

- Helin T, Mäkinen-Kiljunen S. Occupational asthma and rhinoc-onjunctivitis caused by senna. *Allergy* 1996; 51: 181–4.
- 2. Baggaley P. A shared allergy. Pharm J 1997; 259: 724. Marks GB, et al. Asthma and allergy associated with occupation-al exposure to ispaghula and senna products in a pharmaceutical work force. Am Rev Respir Dis 1991; 144: 1065–9.
- 4. Fujita Y, et al. A case of interstitial granulomatous drug reaction due to sennoside. Br J Dermatol 2004; 150: 1035-7.

Precautions

Senna should not be given to patients with nausea or vomiting, undiagnosed abdominal pain, or intestinal obstruction; care should also be taken in patients with inflammatory bowel disease. Prolonged use should generally be avoided.

Although anthraquinone derivatives may be distributed into breast milk the concentration achieved after usual maternal dosage is thought to be insufficient to affect the nursing infant (see also below).

Breast feeding. No adverse effects have been seen in breastfed infants whose mothers were receiving senna, and the Amer-ican Academy of Pediatrics considers¹ that it is therefore usually compatible with breast feeding.

- 1. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. *Pediatrics* 2001; **108**: 776–89. Correction. *ibid*.; 1029. Also available at:
- http://aappolicy.aappublications.org/cgi/content/full/ pediatrics%3b108/3/776 (accessed 21/11/06)

Colonic perforation. There were early reports of colonic per-foration with faecal peritonitis, ¹² in one case fatal, ¹ after use of a senna preparation containing total sennosides 142 mg for bowel preparation before barium enema. In 1985, the strength of the UK preparation was halved to contain 72 mg of total sennosides; it was subsequently withdrawn, although a similar preparation, at the higher strength, remains available in some countries. To reduce the risk of colonic perforation, patients with suspected stricture, inflammatory bowel disease, or impending obstruction should not receive a bowel stimulant.2

- Galloway D, et al. Faecal peritonitis after laxative preparation for barium enema. BMJ 1982; 284: 472.
- 2. Cave-Bigley D. Faecal peritonitis after laxative preparation for barium enema. BMJ 1982; 284: 740.

Pharmacokinetics

There is some absorption of anthraquinone laxatives after oral doses. Absorbed anthraquinones are metabolised in the liver. Unabsorbed senna is hydrolysed in the colon by bacteria to release the active free anthraquinones. Anthraquinones are excreted in urine and faeces and distributed into breast milk.

Uses and Administration

Senna is an anthraquinone stimulant laxative (p.1693) that is used to treat constipation (p.1693) and for bowel evacuation before investigational procedures or surgery. The active anthraquinones are liberated into the colon from the sennoside glycosides by colonic bacteria and an effect usually occurs within 6 to 12 hours of an oral dose.

For constipation, senna is usually given as tablets, granules, or syrup. In some countries it is available as suppositories. In the UK, doses of senna preparations are usually expressed in terms of total sennosides calculated as sennoside B. The usual adult oral dose is 15 to 30 mg as a single dose at bedtime. (For doses in children see Administration in Children, below.) In the USA, the usual adult dose is 15 to 30 mg once or twice daily, expressed in terms of total sennosides.

For bowel evacuation before investigational procedures, a dose of 105 to 157.5 mg of sennosides may be given orally as a liquid preparation on the day before the procedure (but see Colonic Perforation under Precautions, above).

The purified sennosides (sennosides A and B), and their calcium salts (calcium sennoside A and calcium sennoside B) are used similarly to senna.

Homoeopathy. Senna leaf has been used in homoeopathic medicines under the following names: Senna; Senna folium.

Administration in children. In the UK, the following oral doses of sennosides are licensed for use for constipation in children:

- aged 2 to 6 years: 3.75 to 7.5 mg once daily in the morning
- aged 6 to 12 years: 7.5 to 15 mg once daily at night or in the morning

· 12 years and over: 15 to 30 mg once daily, usually at bedtime In addition, although not licensed for use in children under 2 years, the BNFC allows for an oral dose of syrup (containing sennosides 7.5 mg per 5 mL) of 0.5 mL/kg (to a maximum of 2.5 mL) once daily in those aged 1 month to 2 years.

Preparations

BP 2008: Senna Liquid Extract; Senna Tablets; Standardised Senna Gran-

Ph. Eur.: Senna Leaf Dry Extract, Standardised; USP 31: Senna Fluidextract; Senna Syrup; Sennosides Tablets.

Proprietary Preparations (details are given in Part 3)

Proprietary Preparations (details are given in Part 3) Arg:: Circela Fibra; Laxinuela; Laxiruela Circela Fibra; Laxuave Sen; Aus-trol.: Bekunis Herbal Tea; Bekunis Instant; Laxettes; SennaPlus; Sennetabs; senokot; Austria: Bekunis; Colonorm; Darmol; Dragees; Neurzehn Sen-nat; X-Prep; Belg:: Darlin; Fuca; Midro†; Prunasine; Senokot; Transix; Ernas; Sens; Ganda; Agarol Extra; Agarol with Sennosides; Ex-Lax; Experience; Glysennid; GNC Herbal Laxative; Herbal Laxative; Laxative; Bills; Sennapre; Sennatab; Senokot; X-Prep; Chile: Cholax; Naturiax; Cz.: Caj z Listu Senny; List Senny; Regulax;†; Sennove Lusky; Sennovy List; Tisas-ent; X-Prep; Demm: Pursennid; Fin.: Experp; Pursennid; Sennapur; Fr.: Senokot; X-Prep; Gen: Abfuhritee N; Bekunis Instant; Bekunis; Herstant; Tekunis; Pruchtewurfe; Ramend; Regulax;†; X-Prep; Gnie: Bekunis; Presennid†; X-Prep; Hoenkot; Srade; Bekunis; N-Zax; Finita; Bekunis; Circuelax; Com; Circuelax; TL: Lagenbach; Senokot; X-Prep; Norw: Senokot; X-Prep; X2: Senokot; Philipp:: Senokot; X-Prep; Norw: Senokot; X-Prep; X2: Senokot; Sofiax; X-Prep; Senokot; X-Prep; Norw: Senokot; X-Prep; X2: Senokot; Sofiax; X-Prep; Senokot; X-Prep; Norw: Senokot; X-Prep; X2: Senokot; Sofiax; X-Prep; Senokot; X-Prep; Norw: Senokot; X-Prep; X2: Gavenna (Faace+na); SAfr:: Back Forest; Depurar; Gal; Hamburg Tea; Sennata; Senefol; X-Prep; Singapore; Senokot; X-Prep; Moriz: Gavena (Taace+na); SAfr:: Back Forest; Depurar; Gal; Hamburg Tea; Senalax; Senehot; Sofiax; X-Prep; Singapore; Senokot; Spain; Diolaxif; Justelax; Laxatte Bescansa; Normai; Laxatte Olan; Lax-atte Salud; Jatata; X-Prep; Swed; Pursennid; Svitz; Lax; Senokot; X-Prep; Thai: Senokot; X-Prep; Swed; Pursennid; Svitz; Lax; Senokot; X-Prep; Thai: Senokot; X-Nerey; Xenna; Port; Bekuns; Laxatte Olan; Lax-atte Salud; Jatata; X-Prep; Swed; Pursennid; Svitz; Lax; CySA; Back-Torught; Dosalfex; Dr: Edwards; Olive; Evac-U-Gen; Sc-Lax; Fletcher; Castoria; Lax; Puls; Litte; Laxat; Y-Rep; Senokot; Sure-Lax; Senokot; X-H; UAE; Laxat;

 Pills Little Turmys Laxative; Maximum Relief Ex-Lax Senexon; Senna-Gen; Senokot; Senokot; X-Prep; Venez.; Laxovar; Senlax; Senokot.
 Multi-ingredient: Arg.: Agiolax; Calculina⁺; Candilax; Cirulaxia; Gelax; Kronolax; LX-30; Medilaxan; Promyt; Raplax; Fibras; Austrol: Agiolax; Commists Own Natural Laxative with Softener; Coloxyl with Senna; Combilax; Neo Celanse; Pertone; Prolax; Sennesof; Softax, Austra: Abfuhrtee; Figeletter, Herelax, Illings Bozner, Mayur-Teet; Laxonon; Herabi, Frugelettern, Herelax; Illings Bozner, Mayur-Teet; Laxonon; Herabi, Frugelettern, Herelax; Millings Bozner, Mayur-Teet; Agiolax; Caralax; Frugelettern, Herelax; Illings Bozner, Mayur-Teet; Haron Tee; Mido, Tee; Neda Teuchtewurfe; Planta Lax; Pursennid; Sabatif; The Chambard-Tee; Belg:: Agiolax; Depuratif des Alpes; Turtlax; Laxainne; Laxainne; Laxatine; Harnat-T; Sene Composta; Tamarit; Tamarine; Tamarit; Canad:, Cholasyn I; Cholasyn I; Cholasyn; Chortola; Frutalax; Laxainne; Laxative; Dillie; Blaki, Instalax; Melax; Hurdax; Tamarine; Te Laxative; Chile; Blaki, Instalax; Melax; Murdax; Tamarine; Te. Theiss Schweden Krauter; Dri Theiss Schweden Krauter; Projima; Reduktar, Senalax; Denm:, Figen; Fin.: Agiolax; Gr: Agiolax; Grains de Vals; Herbalax; Laxative plus; Medilfor Tisane Hepatique No 5; Modane; Mucinum Cascara; Hurge: Bloku; Instalax; Medilfor Tisane Contre la Constipation Passagere No 7; Medilfor Tisane Hepatique No 5; Modane; Mucinum Cascara; Hurge: Bloku Laxater; Horge: Mong: Agiolax; Grains de Vals; Herbeelax; Eucarbon; Meelax; Laxative; Julie; Agiolax; Ciruada; Gens; Agiolax; Contex, Maron; Kalax; Kalas; Kalas; Kalas; Kalas; Kuretter; Horge: Agiolax; Contex, Maron; Kalas; Kalas; Kuretter; Korge, Kalas; Kalas; Kuretter; Korge, Kalas; Kalas Venez.: Agiolax; Fibralax+; Rheu-Tarx 1; Senokot con Docusato; Senokot con Fibra†

Simeticone (BAN, rINN)

Activated Dimethicone: Activated Dimethylpolysiloxane: Activated Dimeticone; Antifoam A; Antifoam AF; Simethicone (US-AN): Simeticona: Siméticone: Simeticonum: Simetikon: Simetikonas; Simetikoni; Szimetikon.

Симетикон

CAS - 8050-81-5.

NOTE. Do not confuse with Dimeticone (p.2032).

Compounded preparations of simeticone may be represented by the following names:

Co-simalcite x/y (BAN)—where x and y are the strengths in milligrams of simeticone and hydrotalcite respectively.

Pharmacopoeias. In Eur. (see p.vii) and US.

Ph. Eur. 6.2 (Simeticone). It is prepared by incorporation of 4 to 7% silica into poly(dimethylsiloxane) with a degree of polymerisation between 20 and 400. It contains 90.5 to 99.0% of poly(dimethylsiloxane). It is a greyish-white, opalescent, viscous liquid. Practically insoluble in water and in methyl alcohol: very slightly soluble to practically insoluble in dehydrated alcohol; partly miscible with dichloromethane, with ethyl acetate, with methyl ethyl ketone, and with toluene.

USP 31 (Simeticone). A mixture of fully methylated linear siloxane polymers containing repeating units of the formula [-(CH₃)₂SiO-]_n, stabilised with trimethylsiloxy end-blocking units of the formula [(CH₃)₃SiO-], and silicon dioxide. It contains not less than 90.5% and not more than 99% of polydimethylsiloxane and not less than 4% and not more than 7% of silicon dioxide. A translucent, grey, viscous fluid. Insoluble in water, in alcohol, and in dehydrated alcohol; the liquid phase is soluble 1 in 10 of chloroform, of ether, and of benzene, leaving a residue of silicon dioxide. Store in airtight containers.

Profile

Simeticone is a mixture of liquid dimeticones containing finely divided silicon dioxide to enhance the defoaming properties of the silicone. It lowers surface tension and when given by mouth causes bubbles of gas in the gastrointestinal tract to coalesce, thus aiding their dispersion.

Simeticone is used for the relief of flatulence and abdominal discomfort due to excess gastrointestinal gas in disorders such as dyspepsia (p.1695) and gastrooesophageal reflux disease (p.1696). Doses of 100 to 250 mg three or four times daily have been given. For many gastrointestinal disorders, it is given with an antacid.

Doses of about 20 to 40 mg of simeticone have been given with feeds to relieve colic in infants (see Gastrointestinal Spasm, p.1696).

Simeticone is also used as a defoaming agent in radiography or endoscopy of the gastrointestinal tract.

A brief review of the use of simeticone for gastrointestinal symptoms concluded that although it was commonly prescribed with an antacid, there was no good evidence that this provided additional benefit. When used alone simeticone probably helped to relieve minor postoperative and postprandial symptoms and was a useful aid in upper gastrointestinal endoscopy.1 However, some considered there was no convincing evidence that simeticone, alone or with antacids, was effective for the treatment of eructation, flatulence, or other signs or symptoms of excess gastrointestinal gas.

- Anonymous. Dimethicone for gastrointestinal symptoms? Drug Ther Bull 1986; 24: 21–2.
- 2. Anonymous. Simethicone for gastrointestinal gas. Med Lett Drugs Ther 1996; 38: 57-8.

Preparations

BP 2008: Simeticone for Oral Use; Simeticone Suspension for Infants; USP 31: Alumina, Magnesia, and Simethicone Oral Suspension; Alumina, Magnesia, and Simethicone Tablets; Alumina, Magnesia, Calcium Carbonate, and Simethicone Tablets; Calcium Carbonate, Magnesia, and Simethicone Tablets; Magaldrate and Simethicone Oral Suspension; Magaldrate and Simethicone Tablets; Simethicone Capsules; Simethicone Emulsion; Sime thicone Oral Suspension; Simethicone Tablets.

Proprietary Preparations (details are given in Part 3)

Proprecary Preparations (details agiven in Parts): Arg:: Aesim, Alat: Carbogasis (carbogasis [orte: Bayen Antigas: Factor AG; Metiorisan: Mylanta Gas; Simecon: Austral.: Degas; Degas Infant Dropst; Infacol; Medefoam; Austria: Antifat: Disflatyl; Lefaxin; SAB Sim-plex; Braz: Anflat; Dimezin; Espasmo Flatol; Finigas; Flatex; Flatol; For Gas; Freegas; Gastroflat; Gazyme; Luftai, Luftrin; Meticone; Mylanta Hus; Mylicor; Nogas; Tsanagas; Silidrov; Candd: Gas: X; Ovol; Pnazyme; Silgaz; Chile: Rapex; Gasoff; Gasorbol; Pepsidol; Cz.: Ceolat; Disflatyl; Espunisar; Lefax; SAB Simplex; Oema: Aeropax; Mylicor; Fini: Cuplator; Disflatyl; Minfom; Fr.: Silgaz; Ger.: Absorber HPV; Aegrosan; Ceolat; Euglator; Disflatyl; Minfom; Fr.: Silgaz; Ger.: Absorber HPV; Aegrosan; Ceolat; Euglator; Disflatyl; Minfom; Fr.: Silgaz; Ger.: Absorber HPV; Aegrosan; Ceolat; Hung:: Espunisar; Infacol; SAB Simplex; Chanz; Infacol; Hong Kong; Air:X; Dentinox; Colic: Drops; Disflatyl; Gascon; Gasteel; Infacol; Ovol; Hung:: Espunisar; Infacol; SAB Simplex; India:: Dimot; Tricaine-HPS; In-don:: Aeroson; Disflatyl; Flatunic; IrI: Infacol; Israel: Gazim; X; Simicol; Hung:: Espunisar; Infacol; SAB Simplex; Candd; Israel: Gazim; X; Simicol; Dentinox; Colic: Drops; Disflatyl; Gascoal; Gastyl; Mex:: Diflatyl; Espunisan (Dentinox; Colic: Espunisar; Isputicon; Gastrosl; Infacol; Malprie; Dis-flatyl; Pol.: Bobotic; Espunisar; Esputicon; Gastrosl; Infacol; Halp; Dis-flatyl; Pol.: Bobotic; Espunisar; Esputicon; Gastrosl; Infacol; Halp; Dis-Flatyn; Pol.: Bobotic; Espunisar; Esputicon; Gastrosl; Infacol; Manti Gastop; Jelament; Singopore: Cuplator; Gascoal; Infacol; Hardon; Sumisar; Aero Red; Enterosilicona; Swed:: Minifom; Siwaz; Disflatyl; Hatulex; Lefax; Polysi Iane; Singet-AF; Thol:: AirX; Airrox; Babcon; BlowX; Disflatyl; Gas-MM; Gas-X; Gassi; Gastyl; Logastin; Mylom; Ovol; Semet; Noz; Simac); Arg.: Aesim; Aflat; Carbogasol; Carbogasol Forte; Espaven Antigas; Factor